Profil penggunaan obat antidiabetes pada pasien diabetes mellitus tipe 2 di instalasi rawat jalan RSUD Provinsi NTB tahun 2018
DOI:
10.29303/sjp.v2i1.74Downloads
Abstract
Diabetes mellitus (DM) is a disorder of insulin secretion, insulin action or both, which are characterized by blood glucose levels > 200 mg/dl and / or fasting blood glucose levels > 126 mg/dl. In 2017 Indonesia was recorded as the sixth largest country with DM in the world. The most common classification of diabetes is type 2 DM with an incidence 90-95%. The study aimed to determine the profile of antidiabetic use in type 2 DM patients at the outpatient installation of RSUD Provinsi NTB in 2018. This study used cross sectional design retrospectively with purposive sampling method for the period January-December 2018. The results showed that in 112 patients, 195 antidiabetic agents were prescribed. The antidiabetic prescribed were metformin (33.85%), glimepirid (25.13%), aspart insulin (13.33%), insulin detemir (8.21%), pioglitazone (6.67%), insulin glargine (6.67%), glyclazide (1.54%), gliquidone (1.54%), acarbose (1.54), regular insulin (1.03%), and insulin lispro (0.51%). Overall, antidiabetic use was in accordance with the guideline recommendations. Further research is needed regarding the review of prescriptions and detailed indications in order to increase rationality of drug use, reduce morbidity and mortality and reduce medical costs.Keywords:
Type 2 DM, blood glucose, outpatient, antidiabetic, metforminReferences
Almasdy, D., Sari, D. P., Suhatri, S., Darwin, D., & Kurniasih, N. (2015). Evaluasi Penggunaan Obat Antidiabetik Pada Pasien Diabetes Melitus Tipe-2 di Suatu Rumah Sakit Pemerintah Kota Padang – Sumatera Barat. Jurnal Sains Farmasi & Klinis, 2(1), 104. https://doi.org/10.29208/jsfk.2015.2.1.58
American Diabetes Association. (2018). Standards of Medical Care in Diabetes 2018. The Journal OfClinical and Applied Research and Education, 41, 2045–2047. https://doi.org/10.2337/dc18-su09
American Diabetes Association. (2019a). 9. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes - 2019. Diabetes Care, 42(supp 1), S90–S102. https://doi.org/10.2337/dc19-S009
American Diabetes Association. (2019b). Standards of Medical Care In Diabetes - 2019. Diabetes Care, Supp 1.
Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., & Malanda, B. (2018). IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Research and Clinical Practice, 138, 271–281. https://doi.org/10.1016/j.diabres.2018.02.023
Dinas Kesehatan NTB. (2017). Profil Kesehatan Provinsi Nusa Tenggara Barat Tahun 2017. In Provinsi Nusa Tenggara Barat Tahun 2017. Dinas Kesehatan Provinsi Nusa Tenggara Barat.
Edwina, D., & Manaf, A. (2015). Pola Komplikasi Kronis Penderita Diabetes Melitus Tipe 2 Rawat Inap di Bagian Penyakit Dalam RS. Dr. M. Djamil Padang. Jurnal Kesehatan Andalas, 4(1), 102–106. http://jurnal.fk.unand.ac.id/index.php/jka/article/view/207
International Diabetes Federation. (2013). IDF Diabetes Atlas Sixth Edition 2013. International Diabetes Federation.
International Diabetes Federation. (2017). IDF Diabetes Atlas Eighth Edition 2017. In IDF Diabetes Atlas, 8th edition. International Diabetes Federation. https://doi.org/http://dx.doi. org/10.1016/S0140-6736(16)31679-8.
Isnaini, N., & Ratnasari, R. (2018). Faktor risiko mempengaruhi kejadian Diabetes mellitus tipe dua. Jurnal Kebidanan Dan Keperawatan Aisyiyah, 14(1), 59–68. https://doi.org/10.31101/jkk.550
Kautzky-Willer, A., Harreiter, J., & Pacini, G. (2016). Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. In Endocrine Reviews (Vol. 37, Issue 3, pp. 278–316). Endocrine Society. https://doi.org/10.1210/er.2015-1137
Kurniawan, I. (2010, December). Diabetes Melitus Tipe 2 pada Usia Lanjut. Majalah Kedokteran Indonesia, 60(12), 576–584. https://doi.org/10.3928/0098-9134-19941101-20
Murad, M. A., Abdulmageed, S. S., Iftikhar, R., & Sagga, B. K. (2014). Assessment of the common risk factors associated with type 2 diabetes mellitus in jeddah. International Journal of Endocrinology, 1–9. https://doi.org/10.1155/2014/616145
PB PERKENI. (2015). Konsensus Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia 2015. PB Perkeni.
Prasetyani, D., & Sodikin. (2017). Analisis Faktor Yang Mempengaruhi Kejadian Diabetes Melitus (DM) Tipe 2. Jurnal Kesehatan Al Irsyad, 10(2), 1–9.
Psarakis, H. M. (2006). Clinical challenges in caring for patients with diabetes and cancer. Diabetes Spectrum, 19(3), 157–162. https://doi.org/10.2337/diaspect.19.3.157
Putra, I. D. G. I. P., Wirawati, I. A. P., & Mahartini, N. N. (2019). Hubungan Kadar Gula Darah dengan Hipertensi pada Pasien Diabetes Mellitus Tipe 2 di RSUP Sanglah. Intisari Sains Medis, 10(3), 797–800. https://doi.org/10.15562/ism.v10i3.482
Rizos, C. V., Elisaf, M. S., Mikhailidis, D. P., & Liberopoulos, E. N. (2009). How safe is the use of thiazolidinediones in clinical practice? Expert Opinion on Drug Safety, 8(1), 15–32. https://doi.org/10.1517/14740330802597821
Sola, D., Rossi, L., Schianca, G. P. C., Maffioli, P., Bigliocca, M., Mella, R., Corlianò, F., Paolo Fra, G., Bartoli, E., & Derosa, G. (2015). Sulfonylureas and their use in clinical practice. Archives of Medical Science, 11(4), 840–848. https://doi.org/10.5114/aoms.2015.53304
Suastika, K., Dwipayana, P., Semadi, M. S., & Kuswardhani, R. A. T. (2012). Age is an Important Risk Factor for Type 2 Diabetes Mellitus and Cardiovascular Disease. Book Citation Index. https://doi.org/10.1016/j.colsurfa.2011.12.014
Van De Laar, F. A., Lucassen, P. L., Akkermans, R. P., Van De Lisdonk, E. H., Rutten, G. E., & Van Weel, C. (2005). α-Glucosidase inhibitors for patients with type 2 diabetes: Results from a Cochrane systematic review and meta-analysis. In Diabetes Care (Vol. 28, Issue 1, pp. 154–163). American Diabetes Association. https://doi.org/10.2337/diacare.28.1.154
Yau, H., Rivera, K., Lomonaco, R., & Cusi, K. (2013). The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus. Current Diabetes Reports, 13(3), 329–341. https://doi.org/10.1007/s11892-013-0378-8
Almasdy, D., Sari, D. P., Suhatri, S., Darwin, D., & Kurniasih, N. (2015). Evaluasi Penggunaan Obat Antidiabetik Pada Pasien Diabetes Melitus Tipe-2 di Suatu Rumah Sakit Pemerintah Kota Padang – Sumatera Barat. Jurnal Sains Farmasi & Klinis, 2(1), 104. https://doi.org/10.29208/jsfk.2015.2.1.58
American Diabetes Association. (2018). Standards of Medical Care in Diabetes 2018. The Journal OfClinical and Applied Research and Education, 41, 2045–2047. https://doi.org/10.2337/dc18-su09
American Diabetes Association. (2019a). 9. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes - 2019. Diabetes Care, 42(supp 1), S90–S102. https://doi.org/10.2337/dc19-S009
American Diabetes Association. (2019b). Standards of Medical Care In Diabetes - 2019. Diabetes Care, Supp 1.
Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., & Malanda, B. (2018). IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Research and Clinical Practice, 138, 271–281. https://doi.org/10.1016/j.diabres.2018.02.023
Dinas Kesehatan NTB. (2017). Profil Kesehatan Provinsi Nusa Tenggara Barat Tahun 2017. In Provinsi Nusa Tenggara Barat Tahun 2017. Dinas Kesehatan Provinsi Nusa Tenggara Barat.
Edwina, D., & Manaf, A. (2015). Pola Komplikasi Kronis Penderita Diabetes Melitus Tipe 2 Rawat Inap di Bagian Penyakit Dalam RS. Dr. M. Djamil Padang. Jurnal Kesehatan Andalas, 4(1), 102–106. http://jurnal.fk.unand.ac.id/index.php/jka/article/view/207
International Diabetes Federation. (2013). IDF Diabetes Atlas Sixth Edition 2013. International Diabetes Federation.
International Diabetes Federation. (2017). IDF Diabetes Atlas Eighth Edition 2017. In IDF Diabetes Atlas, 8th edition. International Diabetes Federation. https://doi.org/http://dx.doi. org/10.1016/S0140-6736(16)31679-8.
Isnaini, N., & Ratnasari, R. (2018). Faktor risiko mempengaruhi kejadian Diabetes mellitus tipe dua. Jurnal Kebidanan Dan Keperawatan Aisyiyah, 14(1), 59–68. https://doi.org/10.31101/jkk.550
Kautzky-Willer, A., Harreiter, J., & Pacini, G. (2016). Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. In Endocrine Reviews (Vol. 37, Issue 3, pp. 278–316). Endocrine Society. https://doi.org/10.1210/er.2015-1137
Kurniawan, I. (2010, December). Diabetes Melitus Tipe 2 pada Usia Lanjut. Majalah Kedokteran Indonesia, 60(12), 576–584. https://doi.org/10.3928/0098-9134-19941101-20
Murad, M. A., Abdulmageed, S. S., Iftikhar, R., & Sagga, B. K. (2014). Assessment of the common risk factors associated with type 2 diabetes mellitus in jeddah. International Journal of Endocrinology, 1–9. https://doi.org/10.1155/2014/616145
PB PERKENI. (2015). Konsensus Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia 2015. PB Perkeni.
Prasetyani, D., & Sodikin. (2017). Analisis Faktor Yang Mempengaruhi Kejadian Diabetes Melitus (DM) Tipe 2. Jurnal Kesehatan Al Irsyad, 10(2), 1–9.
Psarakis, H. M. (2006). Clinical challenges in caring for patients with diabetes and cancer. Diabetes Spectrum, 19(3), 157–162. https://doi.org/10.2337/diaspect.19.3.157
Putra, I. D. G. I. P., Wirawati, I. A. P., & Mahartini, N. N. (2019). Hubungan Kadar Gula Darah dengan Hipertensi pada Pasien Diabetes Mellitus Tipe 2 di RSUP Sanglah. Intisari Sains Medis, 10(3), 797–800. https://doi.org/10.15562/ism.v10i3.482
Rizos, C. V., Elisaf, M. S., Mikhailidis, D. P., & Liberopoulos, E. N. (2009). How safe is the use of thiazolidinediones in clinical practice? Expert Opinion on Drug Safety, 8(1), 15–32. https://doi.org/10.1517/14740330802597821
Sola, D., Rossi, L., Schianca, G. P. C., Maffioli, P., Bigliocca, M., Mella, R., Corlianò, F., Paolo Fra, G., Bartoli, E., & Derosa, G. (2015). Sulfonylureas and their use in clinical practice. Archives of Medical Science, 11(4), 840–848. https://doi.org/10.5114/aoms.2015.53304
Suastika, K., Dwipayana, P., Semadi, M. S., & Kuswardhani, R. A. T. (2012). Age is an Important Risk Factor for Type 2 Diabetes Mellitus and Cardiovascular Disease. Book Citation Index. https://doi.org/10.1016/j.colsurfa.2011.12.014
Van De Laar, F. A., Lucassen, P. L., Akkermans, R. P., Van De Lisdonk, E. H., Rutten, G. E., & Van Weel, C. (2005). α-Glucosidase inhibitors for patients with type 2 diabetes: Results from a Cochrane systematic review and meta-analysis. In Diabetes Care (Vol. 28, Issue 1, pp. 154–163). American Diabetes Association. https://doi.org/10.2337/diacare.28.1.154
Yau, H., Rivera, K., Lomonaco, R., & Cusi, K. (2013). The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus. Current Diabetes Reports, 13(3), 329–341. https://doi.org/10.1007/s11892-013-0378-8
Zilov, A. V., Abdelaziz, S. I., AlShammary, A., Al Zahrani, A., Amir, A., Assaad Khalil, S. H., Brand, K., Elkafrawy, N., Hassoun, A. A. K., Jahed, A., Jarrah, N., Mrabeti, S., & Paruk, I. (2019). Mechanisms of action of metformin with special reference to cardiovascular protection. Diabetes/Metabolism Research and Reviews, 35(7), 1–12. https://doi.org/10.1002/dmrr.3173
License
Authors who publish with Sasambo Journal of Pharmacy (SJP), agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Lisensi Creative Commons Atribusi 4.0 Internasional. This license allows authors to use all articles, data sets, graphics and appendices in data mining applications, search engines, web sites, blogs, and other platforms by providing an appropriate reference. The journal allows the author(s) to hold the copyright without restrictions and will retain publishing rights without restrictions.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Sasambo Journal of Pharmacy
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
